Ventus Therapeutics develops a structural immunology platform

ventus Therapeutics announced the completion of a $60 million round of A-round financing led by Versant Ventures, GV, according to Arterial Network. The proceeds will be used to advance three research and development programs and expand the company's structural immunology platform to address drug targets that were difficult to deal with in the past.Ventus Therapeutics is a biopharmaceutical company dedicated to developing new small molecule drugs for the congenital immune system to treat autoimmune diseases, inflammation and cancer. Its in-house team is working with a team of scientists who have made significant contributions to structural biology and immunology. Currently, Ventus has established an emerging channel for multidrug programs to address key targets in the innant immune system.Dr Marcelo Bigal, President and CEO of Ventus Therapeutics, said, "Ventus' know-how provides an opportunity to develop selective small molecule drugs for innomic immunity, and with the support of Versant and GV, we can now turn the progress of our research into innovative drugs for autoimmune diseases and oncology. Dr, managing director of Versant, said: "When we assembled Ventus, we saw opportunities to address inflammation and nucleic acid-sensitive targets in new ways. Our academic leaders contribute unique knowledge in structural biology and immunology that provides the basis for the company's platform and research approach.The structural immunology platformthe innate immune system's inflammatory small bodies and nucleic acid sensing pathways consist of many proteins, such as NOD-like subjects, gastrogens, and enzymes involved in DNA and RNA sensing. Despite the importance of these targets for treatment, drug development still faces obstacles to molecular structure, direct assay analysis, and chemical deficiency.Ventus Therapeutics' structural immunology platform addresses current barriers by generating and expressing stable mononomies with known targets, including inflammatory small bodies and nucleic acid sensing targets, based on protein engineering capabilities and the necessary expertise. At the same time, this also allows the protein structure to be clarified, so that the previously non-existent direct biochemical and biophysical measurement methods can appear.About Versant VenturesVentures was founded in 1999 as a healthcare investment company dedicated to helping contact entrepreneurs build the next generation of companies. The company invests primarily in various stages of healthcare with a focus on the discovery and development of new therapies. Versant manages $2.3 billion and has offices in Canada, the United States and Europe. Versant has built a team with deep investment, operational and scientific expertise to enable it to build the company on its own. Since the company was founded in 1999, more than 65 Versat companies have successfully completed acquisitions or IPOs.About GVGV was founded in March 2008 and is an investment fund company owned by Google. GV supports innovative and promising new technology companies on its own. GV focuses on and invests early in a number of industries, including consumer Internet, software, clean technology, biotechnology, healthcare and other areas that have not yet been considered. GV has invested in more than 300 companies.GV has built a team of engineers, designers, physicians, scientists, marketers and investors. Together, they support start-ups, enabling them to work with Google at the same time to provide opportunities to leverage the world's top technologies and talent.
(arterial network)